Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

INVESTOR HIGHLIGHTS
Corporate Mission

Corporate Mission

Investor Presentation

Investor Presentation

Our Pipeline

Our Pipeline

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).
Recent Press Releases

Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

Jan 30, 2023

SEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act

Jan 20, 2023

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Jan 18, 2023